Upcoming biologic agents for the treatment of rheumatic diseases.
The development of biologic agents has provided rheumatologists with a variety of new and effective treatment options. The success of early biologics, especially etanercept and infliximab for the treatment of rheumatoid arthritis, has spurred research into novel targets for the management of systemic inflammatory and autoimmune diseases. In addition, existing biologics approved for use in other diseases, such as rituximab, are now under study for the treatment of new indications. This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents.
Shanahan
Joseph C
JC
Division of Clinical Immunology and Rheumatology, University of Alabama-Birmingham, Alabama, USA. joseph.shanahan@ccc.uab.edu
Moreland
Larry W
LW
Carter
Robert H
RH
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000008:administration & dosage* / Q000009:adverse effects; D001691:Biological Therapy / Q000592:standards / Q000639:trends*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D005544:Forecasting; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D011379:Prognosis; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept